Maxigen Biotech Inc. (1783.TW)
TWD 46.3
(-0.43%)
TWD 46.3
(-0.43%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 171.2 Million | 268.33 Million | 117.59 Million | 74.39 Million | 94.41 Million | 170.58 Million |
| Net Income | 193.14 Million | 165.78 Million | 97.46 Million | 76.73 Million | 72.79 Million | 57.3 Million |
| Depreciation & Amortization | 27.61 Million | 29.58 Million | 32.9 Million | 33.19 Million | 32.49 Million | 26.24 Million |
| Deferred income taxes | -33.82 Million | - | -5.21 Million | - | - | - |
| Stock-based compensation | 7.69 Million | 13.48 Million | 2.44 Million | - | - | - |
| Change in working capital | -11.12 Million | 66.81 Million | -9.72 Million | -10.32 Million | -13 Million | 83.15 Million |
| Other non-cash items | -12.3 Million | -7.32 Million | -285 Thousand | -25.21 Million | 2.13 Million | 3.87 Million |
| Investing Cash Flow | -490.24 Million | 10.43 Million | -2.77 Million | 139.13 Million | 42.61 Million | -142.3 Million |
| Investments in PPE | -22.44 Million | -14.44 Million | -15.44 Million | -11.33 Million | -23.73 Million | -20.22 Million |
| Acquisitions | 900 Thousand | 6.28 Million | - | -599 Thousand | -645 Thousand | 669 Thousand |
| Investment purchases | -491.26 Million | 16.55 Million | -13.74 Million | -20.45 Million | -279.26 Million | -385.33 Million |
| Sales/Maturities of investments | 31.4 Million | 16.55 Million | - | 172.3 Million | 346.46 Million | 276.13 Million |
| Other Investing Activities | -8.84 Million | -14.51 Million | 26.41 Million | -781 Thousand | -208 Thousand | -13.54 Million |
| Financing Cash Flow | -41.39 Million | -1.05 Million | 188.69 Million | -271.35 Million | -54.41 Million | -25.72 Million |
| Debt repayment | -50 Thousand | -100 Thousand | -100 Thousand | -214.53 Million | -2.55 Million | -14.87 Million |
| Dividends payments | -42.35 Million | - | -56.26 Million | -54.18 Million | -51.86 Million | -10.84 Million |
| Common Stock Repurchased | - | - | -100 Thousand | - | - | - |
| Common Stock Issuance | 957 Thousand | - | 247.35 Million | - | - | - |
| Other Financing Activities | 957 Thousand | -951 Thousand | -2.19 Million | -2.62 Million | -2.55 Million | - |
| Accounts receivables | 2.81 Million | 9.61 Million | -15.49 Million | 6.05 Million | -19.52 Million | 73.3 Million |
| Accounts payables | -18.82 Million | -4.11 Million | 7.05 Million | -968 Thousand | 2.97 Million | -9.51 Million |
| Inventory | -9.91 Million | 3.68 Million | 8.03 Million | 1.13 Million | -5.49 Million | 11.35 Million |
| Other working capital | 14.79 Million | 57.63 Million | -9.31 Million | -16.53 Million | 9.04 Million | 71.79 Million |
| Cash at beginning of period | 790.94 Million | 513.3 Million | 209.76 Million | 267.64 Million | 184.84 Million | 182.21 Million |
| Cash at end of period | 431.08 Million | 790.94 Million | 513.3 Million | 209.76 Million | 267.64 Million | 184.84 Million |
| Capital Expenditure | -22.44 Million | -14.44 Million | -15.44 Million | -11.33 Million | -23.73 Million | -20.22 Million |
| Effect of forex changes on cash | 573 Thousand | -76 Thousand | 34 Thousand | -56 Thousand | 181 Thousand | 70 Thousand |
| Net cash flow / Change in cash | -359.86 Million | 277.64 Million | 303.54 Million | -57.88 Million | 82.79 Million | 2.62 Million |
| Free Cash Flow | 148.75 Million | 253.89 Million | 102.14 Million | 63.05 Million | 70.68 Million | 150.35 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 47.33 Million | 28.41 Million | 23.72 Million | 193.14 Million | 55.05 Million | 60.95 Million |
| Depreciation & Amortization | 6.7 Million | 6.51 Million | 6.64 Million | 27.61 Million | 7.18 Million | 6.89 Million |
| Deferred income taxes | - | - | 2.63 Million | -33.82 Million | -14.7 Million | -10.43 Million |
| Stock-based compensation | 1.97 Million | 1.62 Million | -3.32 Million | 7.69 Million | 3.67 Million | 3.67 Million |
| Change in working capital | -5.71 Million | 6.79 Million | 30.11 Million | -11.12 Million | -30.48 Million | 14.87 Million |
| Other non-cash items | -3.15 Million | 12.68 Million | -2.96 Million | -12.3 Million | -3.28 Million | -3.29 Million |
| Investing Cash Flow | -7.39 Million | -5.76 Million | -4.94 Million | -490.24 Million | -265 Thousand | -501.57 Million |
| Investments in PPE | -3.48 Million | -8.97 Million | -8.38 Million | -22.44 Million | -3.51 Million | -2.05 Million |
| Acquisitions | - | - | - | 900 Thousand | -8.56 Million | 450 Thousand |
| Investment purchases | - | - | - | -491.26 Million | 9.06 Million | -500.28 Million |
| Sales/Maturities of investments | - | - | - | 31.4 Million | 8.56 Million | 252 Thousand |
| Other Investing Activities | -3.91 Million | 3.2 Million | 3.44 Million | -8.84 Million | -5.81 Million | 68 Thousand |
| Financing Cash Flow | 542 Thousand | 4.7 Million | -41.39 Million | -41.39 Million | 50 Thousand | - |
| Debt repayment | -459 Thousand | - | - | -50 Thousand | -50 Thousand | - |
| Dividends payments | - | - | -42.35 Million | -42.35 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 4.7 Million | 957 Thousand | 957 Thousand | - | - |
| Other Financing Activities | 542 Thousand | 4.7 Million | 957 Thousand | 957 Thousand | - | - |
| Accounts receivables | -43.11 Million | 13.21 Million | 22.11 Million | 2.81 Million | -12.79 Million | 5.81 Million |
| Accounts payables | 23.28 Million | -7.7 Million | -13.64 Million | -18.82 Million | -26.93 Million | 19.01 Million |
| Inventory | 8.17 Million | 7.06 Million | 11.88 Million | -9.91 Million | -10.64 Million | -10.87 Million |
| Other working capital | 8.9 Million | -5.78 Million | 9.76 Million | 14.79 Million | 19.89 Million | 922 Thousand |
| Cash at beginning of period | 483.13 Million | 431.08 Million | 419.92 Million | 790.94 Million | 402.99 Million | 831.73 Million |
| Cash at end of period | 520.78 Million | 483.13 Million | 431.08 Million | 431.08 Million | 419.92 Million | 402.99 Million |
| Capital Expenditure | -3.48 Million | -8.97 Million | -8.38 Million | -22.44 Million | -3.51 Million | -2.05 Million |
| Effect of forex changes on cash | -422 Thousand | -834 Thousand | 669 Thousand | 573 Thousand | -257 Thousand | 174 Thousand |
| Net cash flow / Change in cash | 37.65 Million | 52.05 Million | 11.15 Million | -359.86 Million | 16.92 Million | -428.73 Million |
| Free Cash Flow | 41.44 Million | 44.98 Million | 48.43 Million | 148.75 Million | 13.93 Million | 70.6 Million |
DC
1203
4769
HLNE
SFBI
EUROTEXIND